Immune checkpoint inhibitor-associated myocarditis and coronary artery disease: There may be more than meets the eye!

Eur J Cancer. 2022 Dec:177:194-196. doi: 10.1016/j.ejca.2022.09.028. Epub 2022 Oct 4.

¹ Internal Medicine & Immuno-Oncology (MedI(2)O), Institute for Regenerative Medicine and Biotherapy (IRMB), Saint Eloi Hospital, Montpellier University Hospital, Montpellier, France.
² Cardiology Department INI-CRT PhyMedExp INSERM CNRS CHU de Montpellier Université de Montpellier France, France.
³ Department of Internal Medicine, Multi-Organic Diseases, Local Referral Center for Rare Auto-immune Diseases, Montpellier University Hospital, Montpellier, France.
⁴ Regional Pharmacovigilance Centre, Department of Medical Pharmacology and Toxicology, Montpellier University Hospital, Montpellier, France.
⁵ Cardiology Department INI-CRT PhyMedExp INSERM CNRS CHU de Montpellier Université de Montpellier France, France. Electronic address: francois.roubille@gmail.com.

No abstract available

Keywords: Coronary angiogram; Heart failure; Immune checkpoint blocker; Immune-related adverse events; Myocardial biopsy; Myocarditis.

Publication types